{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:56:09Z","timestamp":1791834969395,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recently, side effects from Dopamine Receptor Agonist Drugs (DAs) in treating pituitary prolactinoma have raised widespread concern. This study explores the incidence and influencing factors of DAs-related side effects in Chinese prolactinoma patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cross-sectional study was conducted. 51 prolactinoma patients treated with DAs, 12 prolactinoma or pituitary microadenoma patients without DAs treatment, and 33 healthy controls were included. The Barratt impulsivity scale-11, Patient Health Questionnaire 9, and the ICD screening questionnaire were all used to evaluate the psychological and physical side effects of DAs. Clinical data of all subjects were collected from their electronic medical records.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The incidence of ICDs in the treated group, the untreated group, and control group was 9.8% (5\/51), 16.7% (2\/12), and 9.1% (3\/33), respectively. In the treated group in particular, there were 1 patient (2%, 1\/51), 2 patients (3.9%, 2\/51), and 2 patients (3.9%, 2\/51) with positive screening for punding, compulsive shopping, and hypersexuality, respectively. In terms of depression, the incidence of \"minimal\", \"mild\" and \"moderate\" depression in the treated group was 62.8% (32\/51), 25.5% (13\/51), and 5.9% (3\/51), respectively. The incidence of physical symptoms was 51.0% (26\/51) in the treated group and gastrointestinal symptoms were the most common symptoms (33.3%, 17\/51). In addition, we found that the various parameters of DAs treatment had no association with the occurrence of physical symptoms or ICDs (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&gt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Chinese prolactinoma patients treated with DAs had a lower incidence of ICDs (9.8%), while gastrointestinal symptoms were common. In this way, more attention should be paid to side effects, especially physical symptoms, in Chinese prolactinoma patients with DAs therapy during follow-up regardless of dose.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12902-022-01009-3","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T08:04:12Z","timestamp":1649664252000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The side effects of dopamine receptor agonist drugs in Chinese prolactinoma patients: a cross sectional study"],"prefix":"10.1186","volume":"22","author":[{"given":"Xiaoan","family":"Ke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengying","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,11]]},"reference":[{"issue":"1","key":"1009_CR1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000495775","volume":"109","author":"D Maiter","year":"2019","unstructured":"Maiter D. Management of Dopamine Agonist-Resistant Prolactinoma. Neuroendocrinology. 2019;109(1):42\u201350.","journal-title":"Neuroendocrinology"},{"issue":"10","key":"1009_CR2","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1056\/NEJMra1810772","volume":"382","author":"S Melmed","year":"2020","unstructured":"Melmed S. Pituitary-Tumor Endocrinopathies. N Engl J Med. 2020;382(10):937\u201350.","journal-title":"N Engl J Med"},{"issue":"6","key":"1009_CR3","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1210\/edrv.22.6.0451","volume":"22","author":"N Ben-Jonathan","year":"2001","unstructured":"Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev. 2001;22(6):724\u201363.","journal-title":"Endocr Rev"},{"issue":"1","key":"1009_CR4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1124\/pr.110.002642","volume":"63","author":"JM Beaulieu","year":"2011","unstructured":"Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011;63(1):182\u2013217.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"1009_CR5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11102-019-00989-1","volume":"23","author":"P Souteiro","year":"2020","unstructured":"Souteiro P, Belo S, Carvalho D. Dopamine agonists in prolactinomas: when to withdraw? Pituitary. 2020;23(1):38\u201344.","journal-title":"Pituitary"},{"key":"1009_CR6","doi-asserted-by":"publisher","unstructured":"Ananthakrishnan S. The Dark Side to Dopamine Agonist Therapy in Rolactinoma Management.\u00a0Endocr Pract. 2017.\u00a0https:\/\/doi.org\/10.4158\/EP161709.CO.\u00a0PMID:28156150.","DOI":"10.4158\/EP161709.CO"},{"issue":"1","key":"1009_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1530\/EJE-18-0682","volume":"180","author":"AG Ioachimescu","year":"2019","unstructured":"Ioachimescu AG, Fleseriu M, Hoffman AR, Vaughan Iii TB, Katznelson L. Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. Eur J Endocrinol. 2019;180(1):31\u201340.","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"1009_CR8","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s40263-015-0293-4","volume":"29","author":"T Tran","year":"2015","unstructured":"Tran T, Brophy JM, Suissa S, Renoux C. Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson\u2019s Disease: A Systematic Review of Observational Studies. CNS Drugs. 2015;29(12):985\u201398.","journal-title":"CNS Drugs"},{"issue":"6","key":"1009_CR9","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/cen.12375","volume":"80","author":"I Bancos","year":"2014","unstructured":"Bancos I, Nannenga MR, Bostwick JM, Silber MH, Erickson D, Nippoldt TB. Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study. Clin Endocrinol. 2014;80(6):863\u20138.","journal-title":"Clin Endocrinol"},{"key":"1009_CR10","doi-asserted-by":"publisher","first-page":"579606","DOI":"10.3389\/fendo.2020.579606","volume":"11","author":"JM Hinojosa-Amaya","year":"2020","unstructured":"Hinojosa-Amaya JM, Johnson N, Gonz\u00e1lez-Torres C, Varlamov EV, Yedinak CG, McCartney S, et al. Depression and Impulsivity Self-Assessment Tools to Identify Dopamine Agonist Side Effects in Patients With Pituitary Adenomas. Front Endocrinol (Lausanne). 2020;11:579606.","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"7","key":"1009_CR11","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1210\/jc.2018-02202","volume":"104","author":"SC Dogansen","year":"2019","unstructured":"Dogansen SC, Cikrikcili U, Oruk G, Kutbay NO, Tanrikulu S, Hekimsoy Z, et al. Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study. J Clin Endocrinol Metab. 2019;104(7):2527\u201334.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1009_CR12","first-page":"10129","volume":"33","author":"P Chanson","year":"2019","unstructured":"Chanson P, Maiter D. The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new. Best Pract Res Clin Endocrinol Metab. 2019;33(2):10129.","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"issue":"31","key":"1009_CR13","first-page":"2406","volume":"94","author":"Chinese Pituitary adenoma Cooperative Group (2014)","year":"2014","unstructured":"Chinese Pituitary adenoma Cooperative Group (2014). Consensus on diagnosis and treatment of pituitary prolactin adenoma in China (2014 edition). Natl Med J China. 2014;94(31):2406\u201311 (in Chinese).","journal-title":"Natl Med J China"},{"issue":"3","key":"1009_CR14","first-page":"161","volume":"51","author":"Endocrinology Group","year":"2016","unstructured":"Endocrinology Group. Society of Obstetrics and Gynecology, Chinese Medical Association. Consensus on diagnosis and treatment of hyperprolactinemia in women. Chin J Obstet Gynecol. 2016;51(3):161\u20138 (in Chinese).","journal-title":"Chin J Obstet Gynecol"},{"issue":"2","key":"1009_CR15","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96(2):273\u201388.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1009_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.2165\/00002018-199614040-00003","volume":"14","author":"J Webster","year":"1996","unstructured":"Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf. 1996;14(4):228\u201338.","journal-title":"Drug Saf"},{"issue":"14","key":"1009_CR17","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1056\/NEJM199410063311403","volume":"331","author":"J Webster","year":"1994","unstructured":"Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med. 1994;331(14):904\u20139.","journal-title":"N Engl J Med"},{"issue":"2","key":"1009_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s12020-015-0727-2","volume":"51","author":"S Noronha","year":"2016","unstructured":"Noronha S, Stokes V, Karavitaki N, Grossman A. Treating prolactinomas with dopamine agonists: always worth the gamble? Endocrine. 2016;51(2):205\u201310.","journal-title":"Endocrine"},{"issue":"5","key":"1009_CR19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/WNF.0b013e3182281b2f","volume":"34","author":"J Martinkova","year":"2011","unstructured":"Martinkova J, Trejbalova L, Sasikova M, Benetin J, Valkovic P. Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas. Clin Neuropharmacol. 2011;34(5):179\u201381.","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"1009_CR20","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s12020-018-1744-8","volume":"62","author":"E Celik","year":"2018","unstructured":"Celik E, Ozkaya HM, Poyraz BC, Saglam T, Kadioglu P. Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1\u2009year follow-up. Endocrine. 2018;62(3):692\u2013700.","journal-title":"Endocrine"},{"issue":"3","key":"1009_CR21","doi-asserted-by":"publisher","first-page":"dgz076","DOI":"10.1210\/clinem\/dgz076","volume":"105","author":"SMC De Sousa","year":"2020","unstructured":"De Sousa SMC, Baranoff J, Rushworth RL, Butler J, Sorbello J, Vorster J, et al. Impulse Control Disorders in Dopamine Agonist-Treated Hyperprolactinemia: Prevalence and Risk Factors. J Clin Endocrinol Metab. 2020;105(3):dgz076.","journal-title":"J Clin Endocrinol Metab"},{"key":"1009_CR22","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/bs.irn.2017.04.006","volume":"133","author":"D Weintraub","year":"2017","unstructured":"Weintraub D, Claassen DO. Impulse Control and Related Disorders in Parkinson\u2019s Disease. Int Rev Neurobiol. 2017;133:679\u2013717.","journal-title":"Int Rev Neurobiol"},{"issue":"2","key":"1009_CR23","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1007\/s12020-016-1088-1","volume":"55","author":"SM De Sousa","year":"2017","unstructured":"De Sousa SM, Chapman IM, Falhammar H, Torpy DJ. Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists. Endocrine. 2017;55(2):618\u201324.","journal-title":"Endocrine"},{"issue":"5","key":"1009_CR24","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/archneurol.2010.65","volume":"67","author":"D Weintraub","year":"2010","unstructured":"Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589\u201395.","journal-title":"Arch Neurol"},{"issue":"3","key":"1009_CR25","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/mds.25291","volume":"28","author":"J Bastiaens","year":"2013","unstructured":"Bastiaens J, Dorfman BJ, Christos PJ, Nirenberg MJ. Prospective cohort study of impulse control disorders in Parkinson\u2019s disease. Mov Disord. 2013;28(3):327\u201333.","journal-title":"Mov Disord"},{"issue":"2","key":"1009_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.5694\/j.1326-5377.2009.tb02289.x","volume":"190","author":"H Falhammar","year":"2009","unstructured":"Falhammar H, Yarker JY. Pathological gambling and hypersexuality in cabergoline-treated prolactinoma. Med J Aust. 2009;190(2):97.","journal-title":"Med J Aust"},{"issue":"4","key":"1009_CR27","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1176\/jnp.2007.19.4.473","volume":"19","author":"M Davie","year":"2007","unstructured":"Davie M. Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma. J Neuropsychiatry Clin Neurosci. 2007;19(4):473\u20134.","journal-title":"J Neuropsychiatry Clin Neurosci"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-01009-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-022-01009-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-01009-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T08:13:21Z","timestamp":1649664801000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-022-01009-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,11]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1009"],"URL":"https:\/\/doi.org\/10.1186\/s12902-022-01009-3","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,11]]},"assertion":[{"value":"22 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was in accordance to guidelines of Declaration of Helsinki and approved by the Ethics Committee of Peking Union Medical College Hospital (ethical code: ZS-1083). All subjects sign written informed consent forms prior to their participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data in the current study are available from the corresponding author upon reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"The authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"97"}}